
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7608187/publications.pdf Version: 2024-02-01



HONCRINU

#	Article	IF	CITATIONS
1	Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis. National Science Review, 2022, 9, .	4.6	4
2	Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	14
3	LKB1 deficiency upregulates RELM-α to drive airway goblet cell metaplasia. Cellular and Molecular Life Sciences, 2022, 79, 1.	2.4	32
4	Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nature Cancer, 2022, 3, 614-628.	5.7	14
5	<i>Nanog</i> maintains stemness of <i>Lkb1</i> â€deficient lung adenocarcinoma and prevents gastric differentiation. EMBO Molecular Medicine, 2021, 13, e12627.	3.3	5
6	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nature Communications, 2021, 12, 866.	5.8	73
7	Chromobox 4 facilitates tumorigenesis of lung adenocarcinoma through the Wnt/β-catenin pathway. Neoplasia, 2021, 23, 222-233.	2.3	15
8	Lung stem cells in regeneration and tumorigenesis. Journal of Genetics and Genomics, 2021, 48, 268-276.	1.7	4
9	A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks. Genome Biology, 2021, 22, 156.	3.8	17
10	Chromatin assembly factor 1B critically controls the early development but not function acquisition of invariant natural killer T cells in mice. European Journal of Immunology, 2021, 51, 1698-1714.	1.6	0
11	Phase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis. Cell Discovery, 2021, 7, 33.	3.1	34
12	A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis. Journal of Genetics and Genomics, 2021, 48, 571-581.	1.7	2
13	PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer. Journal of Genetics and Genomics, 2021, 48, 640-651.	1.7	21
14	Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. Cancer Immunology Research, 2021, 9, 1298-1315.	1.6	18
15	Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11. Cancer Research, 2021, 81, 5217-5229.	0.4	99
16	Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. National Science Review, 2021, 8, nwab014.	4.6	9
17	Integrative analysis of multiâ€omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer. Clinical and Translational Medicine, 2021, 11, e620.	1.7	6
18	Autophagy inhibition prevents glucocorticoid-increased adiposity via suppressing BAT whitening. Autophagy, 2020, 16, 451-465.	4.3	59

#	Article	IF	CITATIONS
19	The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice. Hepatology, 2020, 71, 1988-2004.	3.6	22
20	Triple-cell lineage tracing by a dual reporter on a single allele. Journal of Biological Chemistry, 2020, 295, 690-700.	1.6	16
21	The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway. Cellular and Molecular Immunology, 2020, 17, 1163-1179.	4.8	40
22	RNA sequencing analysis of small cell lung cancer reveals candidate chemotherapy insensitivity long noncoding RNAs and microRNAs. Annals of Translational Medicine, 2020, 8, 121-121.	0.7	18
23	Specific gut microbiome signature predicts the early-stage lung cancer. Gut Microbes, 2020, 11, 1030-1042.	4.3	138
24	Bi-directional differentiation of single bronchioalveolar stem cells during lung repair. Cell Discovery, 2020, 6, 1.	3.1	587
25	Triple-cell lineage tracing by a dual reporter on a single allele. Journal of Biological Chemistry, 2020, 295, 690-700.	1.6	14
26	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. Journal of Clinical Investigation, 2020, 130, 5924-5941.	3.9	29
27	In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor. PLoS Genetics, 2020, 16, e1009168.	1.5	14
28	Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation. Oncogene, 2019, 38, 6354-6369.	2.6	14
29	Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. Cell Reports, 2019, 28, 512-525.e6.	2.9	59
30	Smart and dual-targeted BSA nanomedicine with controllable release by high autolysosome levels. Colloids and Surfaces B: Biointerfaces, 2019, 182, 110325.	2.5	8
31	YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nature Communications, 2019, 10, 4892.	5.8	256
32	Pathological transition as the arising mechanism for drug resistance in lung cancer. Cancer Communications, 2019, 39, 1-13.	3.7	25
33	ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions. Nature Cell Biology, 2019, 21, 179-189.	4.6	41
34	Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest. Biochemical and Biophysical Research Communications, 2019, 515, 214-221.	1.0	14
35	YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis. Cell Reports, 2019, 27, 1176-1189.e5.	2.9	224
36	Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. Nature Communications, 2019, 10, 1665.	5.8	45

#	Article	IF	CITATIONS
37	Lung regeneration by multipotent stem cells residing at the bronchioalveolar-duct junction. Nature Genetics, 2019, 51, 728-738.	9.4	231
38	VGLL4 plays a critical role in heart valve development and homeostasis. PLoS Genetics, 2019, 15, e1007977.	1.5	40
39	Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1. Journal of Clinical Investigation, 2019, 129, 972-987.	3.9	62
40	Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation. Journal of Clinical Investigation, 2019, 129, 1895-1909.	3.9	49
41	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3978-E3986.	3.3	78
42	The mTOR–S6K pathway links growth signalling to DNA damage response by targeting RNF168. Nature Cell Biology, 2018, 20, 320-331.	4.6	86
43	Targeting <i>HER2</i> Aberrations in Non–Small Cell Lung Cancer with Osimertinib. Clinical Cancer Research, 2018, 24, 2594-2604.	3.2	85
44	Dkk3 dependent transcriptional regulation controls age related skeletal muscle atrophy. Nature Communications, 2018, 9, 1752.	5.8	39
45	Landscape of transcriptional deregulation in lung cancer. BMC Genomics, 2018, 19, 435.	1.2	28
46	SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling. Cell Research, 2017, 27, 540-558.	5.7	57
47	ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3964-E3973.	3.3	54
48	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nature Communications, 2017, 8, 14922.	5.8	80
49	Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma. American Journal of Pathology, 2017, 187, 954-962.	1.9	44
50	Dynamic regulation of CD28 conformation and signaling by charged lipids and ions. Nature Structural and Molecular Biology, 2017, 24, 1081-1092.	3.6	46
51	YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63–GPX2 Axis and ROS Accumulation. Cancer Research, 2017, 77, 5769-5781.	0.4	70
52	Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis. Scientific Reports, 2017, 7, 10407.	1.6	9
53	Metal transporter Slc39a10 regulates susceptibility to inflammatory stimuli by controlling macrophage survival. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12940-12945.	3.3	55
54	Enhancing the precision of genetic lineage tracing using dual recombinases. Nature Medicine, 2017, 23, 1488-1498.	15.2	188

#	Article	IF	CITATIONS
55	Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance. Protein and Cell, 2017, 8, 178-190.	4.8	22
56	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 2579-2586.	0.6	51
57	A novel PHD-finger protein 14/KIF4A complex overexpressed in lung cancer is involved in cell mitosis regulation and tumorigenesis. Oncotarget, 2017, 8, 19684-19698.	0.8	28
58	A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma. Oncotarget, 2017, 8, 33405-33415.	0.8	5
59	Squamous Transition of Lung Adenocarcinoma and Drug Resistance. Trends in Cancer, 2016, 2, 463-466.	3.8	23
60	Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. Cell Research, 2016, 26, 1149-1164.	5.7	26
61	Functional characterization of AMP-activated protein kinase signaling in tumorigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 232-251.	3.3	31
62	MAPK-Mediated YAP Activation Controls Mechanical-Tension-Induced Pulmonary Alveolar Regeneration. Cell Reports, 2016, 16, 1810-1819.	2.9	178
63	Negative regulation of DNMT3A de novo DNA methylation by frequently overexpressed UHRF family proteins as a mechanism for widespread DNA hypomethylation in cancer. Cell Discovery, 2016, 2, 16007.	3.1	74
64	Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Scientific Reports, 2016, 6, 25468.	1.6	44
65	Personalized characterization of diseases using sample-specific networks. Nucleic Acids Research, 2016, 44, e164-e164.	6.5	226
66	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Research, 2016, 22, 4837-4847.	3.2	223
67	Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. Scientific Reports, 2015, 5, 14237.	1.6	51
68	Mechanistic insights into EGFR membrane clustering revealed by super-resolution imaging. Nanoscale, 2015, 7, 2511-2519.	2.8	78
69	Minor Type IV Collagen α5 Chain Promotes Cancer Progression through Discoidin Domain Receptor-1. PLoS Genetics, 2015, 11, e1005249.	1.5	44
70	LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. Cancer Cell, 2015, 27, 698-711.	7.7	118
71	YAP Promotes Malignant Progression of <i>Lkb1</i> -Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin. Cancer Research, 2015, 75, 4450-4457.	0.4	76
72	The RNA-Binding Protein QKI Suppresses Cancer-Associated Aberrant Splicing. PLoS Genetics, 2014, 10, e1004289.	1.5	212

#	Article	IF	CITATIONS
73	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. OncoTargets and Therapy, 2014, 7, 1423.	1.0	41
74	NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. International Journal of Cancer, 2014, 134, 2294-2304.	2.3	53
75	Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nature Communications, 2014, 5, 3261.	5.8	137
76	Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas. Journal of Thoracic Oncology, 2014, 9, 254-258.	0.5	26
77	VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Research, 2014, 24, 331-343.	5.7	238
78	Regulation of EGFR nanocluster formation by ionic protein-lipid interaction. Cell Research, 2014, 24, 959-976.	5.7	109
79	Ubiquitylation of Autophagy Receptor Optineurin by HACE1 Activates Selective Autophagy for Tumor Suppression. Cancer Cell, 2014, 26, 106-120.	7.7	198
80	YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nature Communications, 2014, 5, 4629.	5.8	95
81	Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Research, 2014, 24, 1164-1180.	5.7	235
82	A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer. Cancer Cell, 2014, 25, 166-180.	7.7	476
83	Bantam is essential for Drosophila intestinal stem cell proliferation in response to Hippo signaling. Developmental Biology, 2014, 385, 211-219.	0.9	27
84	Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome. Cancer Letters, 2014, 342, 36-42.	3.2	7
85	Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. European Journal of Medicinal Chemistry, 2014, 77, 75-83.	2.6	20
86	FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 4107-4114.	3.2	125
87	Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression. Cancer Cell, 2014, 25, 590-604.	7.7	332
88	Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors. European Journal of Medicinal Chemistry, 2013, 66, 82-90.	2.6	19
89	ANCCA Protein Expression is a Novel Independent Poor Prognostic Marker in Surgically Resected Lung Adenocarcinoma. Annals of Surgical Oncology, 2013, 20, 577-582.	0.7	26
90	A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity. Cell Research, 2013, 23, 1201-1214.	5.7	81

#	Article	IF	CITATIONS
91	Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Medicine, 2013, 5, 91.	3.6	146
92	Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2013, 56, 4738-4748.	2.9	67
93	MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene. Journal of Biological Chemistry, 2012, 287, 23227-23235.	1.6	213
94	The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by <i>LKB1</i> Loss. Cancer Research, 2012, 72, 6502-6511.	0.4	42
95	The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of <i>ALK</i> Transcripts to Detect <i>ALK</i> Rearrangements in Lung Cancers. Clinical Cancer Research, 2012, 18, 4725-4732.	3.2	86
96	Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains. Journal of Thoracic Oncology, 2012, 7, 85-89.	0.5	82
97	<i>RET</i> Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 4352-4359.	0.8	483
98	A network-based gene-weighting approach for pathway analysis. Cell Research, 2012, 22, 565-580.	5.7	46
99	<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers. Journal of Clinical Oncology, 2012, 30, 863-870.	0.8	1,435
100	Identification of RET gene fusion by exon array analyses in "pan-negative―lung cancer from never smokers. Cell Research, 2012, 22, 928-931.	5.7	74
101	Consensus Rules in Variant Detection from Next-Generation Sequencing Data. PLoS ONE, 2012, 7, e38470.	1.1	30
102	Direct Evidence of Lipid Rafts by in situ Atomic Force Microscopy. Small, 2012, 8, 1243-1250.	5.2	65
103	Effect of the templates on the synthesis of hollow carbon materials as electrocatalyst supports for direct alcohol fuel cells. International Journal of Hydrogen Energy, 2012, 37, 4728-4736.	3.8	29
104	Finding biomarkers for non-small cell lung cancer diagnosis and prognosis. Frontiers in Biology, 2012, 7, 14-23.	0.7	3
105	Temporal Dissection of K-rasG12D Mutant In Vitro and In Vivo Using a Regulatable K-rasG12D Mouse Allele. PLoS ONE, 2012, 7, e37308.	1.1	7
106	LKB1 regulates TCR-mediated PLCÎ <sup>3</sup> 1 activation and thymocyte positive selection. EMBO Journal, 2011, 30, 2083-2093.	3.5	29
107	LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein and Cell, 2011, 2, 99-107.	4.8	39
108	Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers. PLoS ONE, 2011, 6, e28204.	1.1	195

#	Article	IF	CITATIONS
109	Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas. Journal of Thoracic Oncology, 2010, 5, 1130-1135.	0.5	91
110	Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. Cancer Cell, 2010, 17, 547-559.	7.7	215
111	Hollow carbon hemispheres supported palladium electrocatalyst at improved performance for alcohol oxidation. Journal of Power Sources, 2010, 195, 7146-7151.	4.0	43
112	Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutationâ€ŧargeted lung cancer therapy. Cancer Science, 2010, 101, 1933-1938.	1.7	8
113	The serine/threonine kinase LKB1 controls thymocyte survival through regulation of AMPK activation and Bcl-XL expression. Cell Research, 2010, 20, 99-108.	5.7	57
114	Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases. Journal of Clinical Oncology, 2010, 28, 4616-4620.	0.8	313
115	HLungDB: an integrated database of human lung cancer research. Nucleic Acids Research, 2010, 38, D665-D669.	6.5	51
116	LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18892-18897.	3.3	157
117	HER2 <sup>YVMA</sup> drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 474-479.	3.3	163
118	Development of sputtered nanoscale titanium oxide coating on osseointegrated implant devices and their biological evaluation. Vacuum, 2008, 83, 569-574.	1.6	21
119	Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance. Cancer Research, 2008, 68, 5827-5838.	0.4	141
120	Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. Comparative Medicine, 2008, 58, 276-81.	0.4	8
121	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biology and Therapy, 2007, 6, 661-667.	1.5	83
122	Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models. Cancer Research, 2007, 67, 4933-4939.	0.4	155
123	Contents correlation and genetic algorithm based remote sensing images fusion. , 2007, , .		0
124	Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas. Journal of Clinical Investigation, 2007, 117, 346-352.	3.9	44
125	LKB1 modulates lung cancer differentiation and metastasis. Nature, 2007, 448, 807-810.	13.7	907
126	Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. Cancer Cell, 2007, 12, 81-93.	7.7	212

#	Article	IF	CITATIONS
127	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 2006, 9, 485-495.	7.7	427
128	EGFR Targeted Therapy: View from Biological Standpoint. Cell Cycle, 2006, 5, 2072-2076.	1.3	32
129	Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272. Cancer Research, 2006, 66, 6487-6491.	0.4	141
130	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7817-7822.	3.3	248
131	An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 7096-7101.	0.4	250
132	High-resolution genomic profiles of human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9625-9630.	3.3	360
133	Investigating the function of Akt by tet-off inducible expression system. Science Bulletin, 2001, 46, 222-225.	1.7	0
134	Copper induces apoptosis in BA/F3? cells: Bax, reactive oxygen species, and NF?B are involved. Journal of Cellular Physiology, 2000, 184, 161-170.	2.0	67
135	Study on the interaction between Jak3 and IL-2R Î <sup>3</sup> using the yeast two-hybrid system. Science Bulletin, 1999, 44, 1664-1669.	1.7	0
136	The positive and negative control actions of PTPase on IL-2 signaling. Science in China Series C: Life Sciences, 1999, 42, 614-620.	1.3	1
137	Signal for IL-2 internalization located in the endocellular domain of IL-2R Î <sup>3</sup> subunit only. Science Bulletin, 1998, 43, 1390-1394.	1.7	1
138	Freeway traffic systems: prediction and control. , 0, , .		3
139	GoS-based pricing and resource allocation for multimedia broadband networks. , 0, , .		9
140	An economic model for bandwidth allocation in broadband communication networks. , 0, , .		3
141	MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget, 0, 7, 41691-41702.	0.8	68
142	The coordinates of the four corners of image date files and their applications [for date read data]. , 0,		0